

## **Use of Peak Expiratory Flow Rate Monitoring for the Management of Asthma in Adults in the Emergency Department *Policy Resource and Education Paper (PREP)***

This policy resource and education paper (PREP) is an explication of the policy statement “Use of Peak Expiratory Flow Rate Monitoring for the Management of Asthma in Adults in the Emergency Department”

### **Introduction**

The purpose of this paper is to identify the medical literature that pertains to the use of PEFR monitoring for ED management of adult patients with asthma.

This PREP is an update of a previous PREP with the same title, *Use of Peak Expiratory Flow Rate Monitoring for the Management of Asthma in Adults in the Emergency Department* which served as the background information for the policy statement of the same title.<sup>1</sup>

The previous policy statement on this topic<sup>1</sup> originally arose from a number of studies that suggested that peak expiratory flow rate (PEFR) assessment or other spirometric measures were useful in clinical decision-making for patients with acute exacerbations of asthma.<sup>2-14</sup> However, other studies did not find measurement of PEFR in the ED useful in management or in predicting the need for hospital admission.<sup>15-20</sup> Despite the inconsistency of evidence, practice guidelines at the time of the original policy statement recommended the use of PEFR monitoring for patient care in the ED<sup>21</sup> as do more recent guidelines.<sup>22</sup>

There have been additional publications on this topic since the prior policy statement was approved by the ACEP Board of Directors in June 2000. For this revision, a literature search was performed, and recent articles were reviewed. Those references not cited in the prior PREP were systematically graded and may be found in the Evidentiary Table that appears later in this document.

All articles were graded by 2 subcommittee members for strength of evidence and classified by the subcommittee members into 3 classes of evidence on the basis of the design of the study, with design 1 representing the strongest evidence and design 3 representing the weakest evidence for therapeutic, diagnostic, and prognostic clinical reports, respectively (Appendix A). Articles were then graded on 6 dimensions thought to be most relevant: blinded versus nonblinded outcome assessment, blinded or randomized allocation, direct or indirect outcome measures (reliability and validity), biases (eg, selection, detection, transfer), external validity (ie, generalizability), and sufficient sample size. Articles received a final grade (Class I, II, III) on the basis of a predetermined formula taking into account design and quality of study (Appendix B). Articles with fatal flaws were given an “X” grade.

The literature search identified 26 articles not cited in the previous PREP. One Class II study<sup>23</sup> and 7 Class III studies were identified.<sup>24-30</sup> The remainder of the studies were not applicable to the question of use of PEFR in the ED, either because PEFR was not a studied variable, or the study setting was not the ED.<sup>31-48</sup>

## Discussion

Although additional articles were found in the literature update, it appears that the pace of research in this area has slowed. Revisions to the prior policy statement were minor and reflect current evidence-based practices. Many of the critiques noted in the prior PREP remain valid:

1. Investigators were not blinded to PEFr measurements used for disposition decisions.
2. Study asthma treatment studies were different from contemporary treatment protocols.
3. Disposition and outcome criteria were poorly defined.
4. Study sizes were small.
5. Studied patient groups potentially lack generalizability to ED patient populations.

## Summary

The use of PEFr monitoring has not been shown to improve outcomes, reliably predict need for admissions, or limit morbidity or mortality when used during the ED management of adult patients with acute exacerbations of asthma. The decision to perform PEFr monitoring should be individualized for each patient. Although PEFr may aid emergency physicians during their evaluation and treatment of an adult patient with an acute exacerbation of asthma, the evidence does not support requiring PEFr monitoring for all adult patients.

Originally approved June 2000

Revised October 2007

Reaffirmed January 2019

## REFERENCES

1. American College of Emergency Physicians. Use of Peak Expiratory Flow Rate Monitoring for the Management of Asthma in Adults in the Emergency Department. *Ann Emerg Med.* 2001;38:198.
2. Banner AS, Shah RS, Addington WW. Rapid prediction of need for hospitalization in acute asthma. *JAMA.* 1976;235:1337-1338.
3. Bolliger CT, Fourie PR, Kotze D, et al. Relation of measures of asthma severity and response to treatment to outcome in acute severe asthma. *Thorax.* 1992;47:943-947.
4. Brandstetter RD, Gotz VP, Mar DD. Identifying the acutely ill patient with asthma. *South Med J.* 1981;74:713-715.
5. Eliakim R, Halperin Y, Menczel J. A predictor index for hospitalization for patients with acute asthmatic attack. *Isr J Med Sci.* 1984;20:202-206.
6. Fanta CH, Rossing TH, McFadden ER, Jr. Emergency room treatment of asthma. Relationships among therapeutic combinations, severity of obstruction and time course of response. *Am J Med.* 1982;72:416-422.
7. Kelsen SG, Kelsen DP, Fleeger BF, et al. Emergency room assessment and treatment of patients with acute asthma. Adequacy of the conventional approach. *Am J Med.* 1978;64:622-628.
8. McCarren M, Zalenski RJ, McDermott M, et al. Predicting recovery from acute asthma in an emergency diagnostic and treatment unit. *Acad Emerg Med.* 2000;7:28-35.
9. Nowak RM, Pensler MI, Sarkar DD, et al. Comparison of peak expiratory flow and FEV<sub>1</sub> admission criteria for acute bronchial asthma. *Ann Emerg Med.* 1982;11:64-69.
10. Nowak RM, Tomlanovich MC, Sarkar DD, et al. Arterial blood gases and pulmonary function testing in acute bronchial asthma. Predicting patient outcomes. *JAMA.* 1983;249:2043-2046.
11. Rebuck AS, Read J. Assessment and management of severe asthma. *Am J Med.* 1971;51:788-798.
12. Rodrigo G, Rodrigo C. Assessment of the patient with acute asthma in the emergency department. A factor analytic study. *Chest.* 1993;104:1325-1328.

13. Worthington JR, Ahuja J. The value of pulmonary function tests in the management of acute asthma. *CMAJ*. 1989;140:153-156.
14. Nowak RM, Gordon KR, Wroblewski DA, et al. Spirometric evaluation of acute bronchial asthma. *JACEP*. 1979;8:9-12.
15. Emerman CL, Cydulka RK. Factors associated with relapse after emergency department treatment for acute asthma. *Ann Emerg Med*. 1995;26:6-11.
16. Fiel SB, Swartz MA, Glanz K, et al. Efficacy of short-term corticosteroid therapy in outpatient treatment of acute bronchial asthma. *Am J Med*. 1983;75:259-262.
17. Kunitoh H, Nagatomo A, Okamoto H, et al. Predicting the need for hospital admission in patients with acute bronchial asthma. *J Asthma*. 1996;33:105-112.
18. Martin TG, Elenbaas RM, Pingleton SH. Failure of peak expiratory flow rate to predict hospital admission in acute asthma. *Ann Emerg Med*. 1982;11:466-470.
19. Rose CC, Murphy JG, Schwartz JS. Performance of an index predicting the response of patients with acute bronchial asthma to intensive emergency department treatment. *N Engl J Med*. 1984;310:573-577.
20. Stein LM, Cole RP. Early administration of corticosteroids in emergency room treatment of acute asthma. *Ann Intern Med*. 1990;112:822-827.
21. Janson S. National Asthma Education and Prevention Program, Expert Panel Report. II: overview and application to primary care. *Lippincotts Prim Care Pract*. 1998;2:578-588.
22. National Heart, Lung, and Blood Institute. Expert panel report 3: guidelines for the diagnosis and management of asthma, 2007. Accessed at: <http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm> on August 29, 2007.
23. Emerman CL, Woodruff PG, Cydulka RK, et al. Prospective multicenter study of relapse following treatment for acute asthma among adults presenting to the emergency department. MARC investigators. Multicenter Asthma Research Collaboration. *Chest*. 1999;115:919-927.
24. Abisheganaden J, Ng SB, Lam KN, et al. Peak expiratory flow rate guided protocol did not improve outcome in emergency room asthma. *Singapore Med J*. 1998;39:479-484.
25. Choi IS, Koh YI, Lim H. Peak expiratory flow rate underestimates severity of airflow obstruction in acute asthma. *Korean J Intern Med*. 2002;17:174-179.
26. Diner B, Brenner B, Camargo CA, Jr. Inaccuracy of "personal best" peak expiratory flow rate reported by inner-city patients with acute asthma. *J Asthma*. 2001;38:127-132.
27. Piovesan DM, Menegotto DM, Kang S, et al. Early prognosis of acute asthma in the emergency room. *J Bras Pneumol*. 2006;32:1-9.
28. Rodrigo G, Rodrigo C. A new index for early prediction of hospitalization in patients with acute asthma. *Am J Emerg Med*. 1997;15:8-13.
29. Rodrigo G, Rodrigo C. Early prediction of poor response in acute asthma patients in the emergency department. *Chest*. 1998;114:1016-1021.
30. Weber EJ, Silverman RA, Callahan ML, et al. A prospective multicenter study of factors associated with hospital admission among adults with acute asthma. *Am J Med*. 2002;113:371-378.
31. Adams RJ, Boath K, Homan S, et al. A randomized trial of peak-flow and symptom-based action plans in adults with moderate-to-severe asthma. *Respirology*. 2001;6:297-304.
32. Atta JA, Nunes MP, Fonseca-Guedes CH, et al. Patient and physician evaluation of the severity of acute asthma exacerbations. *Braz J Med Biol Res*. 2004;37:1321-1330.
33. Banerji A, Clark S, Afilalo M, et al. Prospective multicenter study of acute asthma in younger versus older adults presenting to the emergency department. *J Am Geriatr Soc*. 2006;54:48-55.
34. Brenner B, Kohn MS. The acute asthmatic patient in the ED: to admit or discharge. *Am J Emerg Med*. 1998;16:69-75.
35. Cowie RL, Revitt SG, Underwood MF, et al. The effect of a peak flow-based action plan in the prevention of exacerbations of asthma. *Chest*. 1997;112:1534-1538.
36. Gibson PG. Monitoring the patient with asthma: an evidence-based approach. *J Allergy Clin Immunol*. 2000;106:17-26.

37. Grunfeld A, Beveridge RC, Berkowitz J, et al. Management of acute asthma in Canada: an assessment of emergency physician behaviour. *J Emerg Med.* 1997;15:547-556.
38. Karras DJ, Sammon ME, Terregino CA, et al. Clinically meaningful changes in quantitative measures of asthma severity. *Acad Emerg Med.* 2000;7:327-334.
39. Marik PE, Varon J, Fromm R, Jr. The management of acute severe asthma. *J Emerg Med.* 2002;23:257-268.
40. McCarren M, McDermott MF, Zalenski RJ, et al. Prediction of relapse within eight weeks after an acute asthma exacerbation in adults. *J Clin Epidemiol.* 1998;51:107-118.
41. Newman KB, Milne S, Hamilton C, et al. A comparison of albuterol administered by metered-dose inhaler and spacer with albuterol by nebulizer in adults presenting to an urban emergency department with acute asthma. *Chest.* 2002;121:1036-1041.
42. Ng TP. Validity of symptom and clinical measures of asthma severity for primary outpatient assessment of adult asthma. *Br J Gen Pract.* 2000;50:7-12.
43. Pesola GR, Xu F, Ahsan H, et al. Predicting asthma morbidity in Harlem emergency department patients. *Acad Emerg Med.* 2004;11:944-950.
44. Richmond NJ, Silverman R, Kusick M, et al. Out-of-hospital administration of albuterol for asthma by basic life support providers. *Acad Emerg Med.* 2005;12:396-403.
45. Tierney WM, Roesner JF, Seshadri R, et al. Assessing symptoms and peak expiratory flow rate as predictors of asthma exacerbations. *J Gen Intern Med.* 2004;19:237-242.
46. Turner MO, Taylor D, Bennett R, et al. A randomized trial comparing peak expiratory flow and symptom self-management plans for patients with asthma attending a primary care clinic. *Am J Respir Crit Care Med.* 1998;157:540-546.
47. Varon J, Fromm RE, Jr. Emergency department care of the asthma patient: predicting "bounce-back" patients. *Chest.* 1999;115:909-911.
48. Wilson MM, Irwin RS, Connolly AE, et al. A prospective evaluation of the 1-hour decision point for admission versus discharge in acute asthma. *J Intensive Care Med.* 2003;18:275-285.

## Evidentiary Table

Study	Year	Design	Intervention(s)/Test(s)/Modality	Outcome Measure/ Criterion Standard	Results	Limitations/Comments	Class
Emerman et al <sup>23</sup>	1999	Multicenter prospective cohort	PEFR one of the factors assessed during initial ED visit	Relapse defined as unscheduled ED return or visit to any physician for worsening symptoms of asthma	PEFR at discharge did not predict relapse; 17% of study group did relapse	PEFR may have been one of the factors used in decision-making for discharge at first ED visit	II
Abisheganaden et al <sup>24</sup>	1998	Prospective paired cohorts	PEFR-driven protocol compared to routine clinical parameter-driven protocol	Discharge PEFR; admission rate	PEFR-guided protocol does not reduce admission rates or demonstrate improved PEFR response compared to clinically guided treatment	Patients not randomized to protocols; treatment periods separated by 1 y; relapse rates not compared	III
Choi et al <sup>25</sup>	2002	Prospective cohort	PEFR and FEV <sub>1</sub> compared at different times in clinical course from ED presentation to 7 days	Spirometric measurements PEFR and FEV <sub>1</sub>	PEFR underestimates severity of airway obstruction in acute asthma compared to FEV <sub>1</sub> measurements	Small study size; only 2 time data points of 0 and 1 h relevant to ED patients	III
Diner et al <sup>26</sup>	2001	Prospective cohort	PEFR obtained by research assistant compared to patient's self-determined personal best	Researcher-obtained PEFR	PEFR – personal best - reported by patients not reliable	Not a study of PEFR in the ED  Inner-city population	III

### Evidentiary Table (continued)

Study	Year	Design	Intervention(s)/Test(s)/Modality	Outcome Measure/ Criterion Standard	Results	Limitations/Comments	Class
Piovesan et al <sup>27</sup>	2006	Prospective cohort	PEFR measured at presentation, 15 min, and 4 h	Favorable outcome if PEFR >50% at 4 h of treatment	Improvement in 15 min PEFR to $\geq 40\%$ was predictive of improvement of 4 h PEFR $\geq 50\%$	PEFR was the outcome measure, not clinical parameters; admissions not reported	III
Rodrigo and Rodrigo <sup>28</sup>	1997	Prospective cohort	Change in PEFR at 30 min (both as percent predicted and absolute flow rate)	Discharge at 3 h if free of dyspnea, use of accessory muscles diminished, wheezing minimal or absent, and able to walk 20 meters without increase in signs or symptoms	3 item index developed for application at 30 min after arrival that included accessory muscle use, PEFR measurement, and change in PEFR from baseline to predict need for admission	Discharge decision based on clinical criteria at 6 h, not measurement of respiratory function; favorable outcome was discharge from ED	III

### Evidentiary Table (continued)

Rodrigo and Rodrigo <sup>29</sup>	1998	Prospective cohort	Change in PEFR at 30 min (both as percent predicted and absolute flow rate)	Discharge at 3 h if free of dyspnea, use of accessory muscles diminished, wheezing minimal or absent, and able to walk 20 meters without increase in signs or symptoms	PEFR measurement and change in PEFR from baseline at 30 min used to develop index validated to predict favorable outcome (FEV <sub>1</sub> >45%)	Discharge decision based on clinical criteria at 3 h, not measurement of respiratory function; favorable outcome was FEV <sub>1</sub> , not PEFR	III
Weber et al <sup>30</sup>	2002	Prospective cohort	PEFR was one of several factors assessed during ED visit	Admissions; ED discharges; relapse as defined by unscheduled visit to physician or ED within 72 h	PEFR <50% of predicted not reliable for predicting relapses; final PEFR in ED was predictive of admission	Retrospective data analysis; PEFR not examined independently for admission decisions; clinicians not blinded to PEFR; admission or discharge decisions not based on PEFR	III

*ED*, emergency department; *FEV<sub>1</sub>*, one-second forced expiratory volume; *h*, hour; *min*, minute; *PEFR*, peak expiratory flow rate; *y*, year.

**Appendix A.** Literature classification schema\*

<b>Design/ Class</b>	<b>Therapy<sup>†</sup></b>	<b>Diagnosis<sup>‡</sup></b>	<b>Prognosis<sup>§</sup></b>
1	Randomized, controlled trial or meta-analyses of randomized trials	Prospective cohort using a criterion standard	Population prospective cohort
2	Nonrandomized trial	Retrospective observational	Retrospective cohort Case control
3	Case series Case report Other (eg, consensus, review)	Case series Case report Other (eg, consensus, review)	Case series Case report Other (eg, consensus, review)

\*Some designs (eg, surveys) will not fit this schema and should be assessed individually.

<sup>†</sup>Objective is to measure therapeutic efficacy comparing  $\geq 2$  interventions.

<sup>‡</sup>Objective is to determine the sensitivity and specificity of diagnostic tests.

<sup>§</sup>Objective is to predict outcome including mortality and morbidity.

**Appendix B.** Approach to downgrading strength of evidence.

---

<b>Downgrading</b>	<b>Design/Class</b>		
	<b>1</b>	<b>2</b>	<b>3</b>
None	I	II	III
1 level	II	III	X
2 levels	III	X	X
Fatally flawed	X	X	X

---